
---
title: '粤开证券：医药生物细分板块分化明显，建议投资者拥抱核心资产'
categories: 
 - 金融
 - 证券时报网
 - 快讯
headimg: 'https://picsum.photos/400/300?random=9394'
author: 证券时报网
comments: false
date: Tue, 22 Jun 2021 14:47:00 GMT
thumbnail: 'https://picsum.photos/400/300?random=9394'
---

<div>   
<p style="text-align: left;">证券时报网讯，粤开证券指出，2021年上半年，医药生物板块走势良好，行业景气度处于上行周期，细分板块集中度不断提升，强者恒强明显。但细分板块分化明显，建议投资者拥抱核心资产，把握结构性投资机会，在结构分化中寻找确定性机会。</p><p style="text-align: left;">1）生物创新药：建议投资者关注两条核心逻辑，一是关注确定性较强、安全边际较高并积极转轨创新的制药企业，这类企业兼顾估值水平较低、分红率较高，成长性良好的特点，如<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="http://info.stcn.com/dc/stock/?stockcode=SZ000963" code="000963">华东医药</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="http://info.stcn.com/dc/stock/?stockcode=SZ002422" code="002422">科伦药业</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="http://info.stcn.com/dc/stock/?stockcode=SS600216" code="600216">浙江医药</a>等。二是建议投资者关注研发投入高，创新能力强的FIC类在研企业，随着企业产品管线的逐步落地，企业未来利润有望大幅改善，建议关注康方生物、康宁杰瑞、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="http://info.stcn.com/dc/stock/?stockcode=SS688180" code="688180">君实生物</a>、信达生物等。</p><p style="text-align: left;">2）CXO行业：建议关注<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="http://info.stcn.com/dc/stock/?stockcode=SZ002821" code="002821">凯莱英</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="http://info.stcn.com/dc/stock/?stockcode=SS603259" code="603259">药明康德</a>、药明生物等CXO龙头企业。</p><p style="text-align: left;">3）疫苗：建议投资者关注疫苗研发能力强、研发及商业化进展居前的疫苗企业，如<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="http://info.stcn.com/dc/stock/?stockcode=SZ300122" code="300122">智飞生物</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="http://info.stcn.com/dc/stock/?stockcode=SS688185" code="688185">康希诺</a>生物、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="http://info.stcn.com/dc/stock/?stockcode=SZ300142" code="300142">沃森生物</a>等。</p><p style="text-align: left;">4）中药：建议投资者关注具有独家品种、布局国际市场的中药企业，如<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="http://info.stcn.com/dc/stock/?stockcode=SS600436" code="600436">片仔癀</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="http://info.stcn.com/dc/stock/?stockcode=SZ000538" code="000538">云南白药</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="http://info.stcn.com/dc/stock/?stockcode=SZ002603" code="002603">以岭药业</a>等。</p><p style="text-align: left;">5）医疗器械：建议重点关注与新冠疫情关联度较高的标的，如<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="http://info.stcn.com/dc/stock/?stockcode=SZ002030" code="002030">达安基因</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="http://info.stcn.com/dc/stock/?stockcode=SS688289" code="688289">圣湘生物</a>等；细分赛道中创新实力强、有望长期享有创新红利的龙头企业，如<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="http://info.stcn.com/dc/stock/?stockcode=SZ300760" code="300760">迈瑞医疗</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="http://info.stcn.com/dc/stock/?stockcode=SZ300832" code="300832">新产业</a>等。</p>
                  
</div>
            